HB 1553 amends Florida’s uterine fibroid research database law to require the Department of Health to include uterine fibroids in the list of diseases issued under section 381.0031(4), Florida Statutes. The bill is narrowly focused and does not create a new program; instead, it expands the disease list tied to an existing database and public awareness framework for uterine fibroids.
The measure also reiterates that the database may not contain any personal identifying information for women diagnosed with or treated for uterine fibroids. The bill would take effect July 1, 2025, and its stated purpose is to support research, education, and public awareness related to uterine fibroids by ensuring the condition is formally included in the state’s disease listing.
Impact
The bill would amend section 381.9312, Florida Statutes, by directing the Department of Health to add uterine fibroids to the list of diseases referenced in the state’s health data and research framework. In practical terms, this would affect how the department categorizes and tracks uterine fibroid-related information for the research database, while preserving existing privacy protections by prohibiting personally identifying information from being included. The bill does not appear to impose new duties on private parties, but it does expand the scope of state health reporting and research infrastructure.
Sentiment
The available legislative record shows no committee transcript debate and no recorded votes, so there is no evidence of significant public disagreement in the materials provided. The bill’s progression suggests it was treated as a targeted health-data measure rather than a controversial policy change. However, its final status indicates it died in the Senate Fiscal Policy committee on June 16, 2025, which means it did not advance to enactment despite the limited scope of the proposal.
Contention
No specific points of contention are documented in the provided transcripts or votes. The only apparent procedural issue is that the bill stalled in Senate Fiscal Policy, which may indicate concern about fiscal impact, committee priorities, or timing rather than opposition to the substance. Because the bill is limited to adding uterine fibroids to an existing disease list and preserving confidentiality, any disagreement likely centered on whether the change was necessary or warranted within the state’s health data system.